Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2021. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction involving the acquisition of American Depositary Shares (ADSs) by Dr. H. Barron, Chief Scientific Officer and President, R&D.
Transaction Details and Commentary
- Transaction Type: Acquisition of notional ADSs within the GSK Executive Supplemental Savings Plan account.
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Volume: 1,207.396 ADSs.
- Price: $38.3500 per ADS.
- Date: May 7, 2021.
- Exchange: New York Stock Exchange (XNYS).
Management commentary, guidance, outlook, risks, and contingencies are not addressed in this specific filing.
Investor Verification Points
- Verify the total holdings of Dr. H. Barron post-transaction to assess insider ownership levels.
- Confirm the market price of GSK ADSs on May 7, 2021, to validate the transaction price of $38.35.
- Review the terms of the GSK Executive Supplemental Savings Plan to understand the mechanics of "notional" acquisitions.